Safety and effectiveness of rasagiline in patients with Parkinson’s disease in Japan: a post-marketing surveillance study

References

• Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912. doi: 10.1016/S0140-6736(14)61393-3
   PubMed Web of Science ®Google Scholar
• Triarhou LC. Dopamine and Parkinson’s disease. In: Madame Curie Bioscience Database Internet. Austin (TX): Landes Bioscience; 2000–2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6271/
   Google Scholar
• Ou Z, Pan J, Tang S, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front Public Health. 2021;9:776847. doi: 10.3389/fpubh.2021.776847
   PubMed Web of Science ®Google Scholar
• GBD. Parkinson’s disease collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global burden of disease study 2016. Lancet Neurol. 2016;17(11):939–953.
   Web of Science ®Google Scholar
• Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–2303. doi: 10.1016/S0140-6736(21)00218-X
   PubMed Web of Science ®Google Scholar
• Lecht S, Haroutiunian S, Hoffman A, et al. Rasagiline - a novel MAO B inhibitor in Parkinson’s disease therapy. Ther Clin Risk Manag. 2007;3(3):467–474.
   PubMedGoogle Scholar
• Wang K, Liu ZH, Li XY, et al. Efficacy and safety of selegiline for the treatment of Parkinson’s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2023;15:1134472. doi: 10.3389/fnagi.2023.1134472
   PubMed Web of Science ®Google Scholar
• Bette S, Shpiner DS, Singer C, et al. Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence. Ther Clin Risk Manag. 2018;14:1737–1745. doi: 10.2147/TCRM.S139545
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002;59(12):1937–1943. doi: 10.1001/archneur.59.12.1937
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361(13):1268–1278. doi: 10.1056/NEJMoa0809335
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241–248. doi: 10.1001/archneur.62.2.241
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with Rasagiline given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947–954. doi: 10.1016/S0140-6736(05)71083-7
   PubMed Web of Science ®Google Scholar
• Hattori N, Takeda A, Takeda S, et al. Rasagiline monotherapy in early Parkinson’s disease: a phase 3, randomized study in Japan. Parkinsonism Relat Disord. 2019;60:146–152. doi: 10.1016/j.parkreldis.2018.08.024
   PubMed Web of Science ®Google Scholar
• Hattori N, Takeda A, Takeda S, et al. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson’s disease patients with wearing-off phenomena: a phase 2/3, randomized, double-blind, placebo-controlled, multicenter study. Parkinsonism Relat Disord. 2018;53:21–27. doi: 10.1016/j.parkreldis.2018.04.025
   PubMed Web of Science ®Google Scholar
• Lew MF, Hauser RA, Hurtig HI, et al. Long-term efficacy of rasagiline in early Parkinson’s disease. Int J Neurosci. 2010;120(6):404–408. doi: 10.3109/00207451003778744
   PubMed Web of Science ®Google Scholar
• Hattori N, Takeda A, Takeda S, et al. Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease. J Neural Transm (Vienna). 2019;126(3):299–308. doi: 10.1007/s00702-018-1964-3
   PubMed Web of Science ®Google Scholar
• Hattori N, Takeda A, Takeda S, et al. Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease. J Neural Transm (Vienna). 2019;126(3):289–297. doi: 10.1007/s00702-018-1962-5
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson’s disease. Expert Opin Drug Saf. 2011;10(4):633–643. doi: 10.1517/14740338.2011.573784
   PubMed Web of Science ®Google Scholar
• AZILECT® (rasagiline mesylate). Tablets for oral use [package insert]. Tokyo. Japan: Takeda Pharmaceutical Company Limited; 2022. Japanese.
   Google Scholar
• AZILECT® (rasagiline tablets). [Package insert]. North (UK PA): TEVA Pharmaceuticals USA, Inc.; 2014.
   Google Scholar
• Reichmann H, Jost WH. Efficacy and tolerability of rasagiline in daily clinical use–a post-marketing observational study in patients with Parkinson’s disease. Eur J Neurol. 2010;17(9):1164–1171. doi: 10.1111/j.1468-1331.2010.02986.x
   PubMed Web of Science ®Google Scholar
• Reichmann H, Klasser M, Apfel R, et al. Efficacy and tolerability of rasagiline in daily clinical use—a post marketing observational study in patients with Parkinson’s disease focusing on non-motor symptoms and QoL. Basal Ganglia. 2015;5(4):101–106. doi: 10.1016/j.baga.2015.09.003
   Google Scholar
• Goetz CG, Schwid SR, Eberly SW, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006;66(9):1427–1429. doi: 10.1212/01.wnl.0000210692.95595.1c
   PubMed Web of Science ®Google Scholar
• Tolosa E, Stern MB. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease. Eur J Neurol. 2012;19(2):258–264. doi: 10.1111/j.1468-1331.2011.03484.x
   PubMed Web of Science ®Google Scholar
• Solís-García Del Pozo J, Mínguez-Mínguez S, de Groot PWJ, et al. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson’s disease. Expert Opin Drug Saf. 2013;12(4):479–486. doi: 10.1517/14740338.2013.790956
   PubMed Web of Science ®Google Scholar
• Prange S, Danaila T, Laurencin C, et al. Age and time course of long-term motor and nonmotor complications in Parkinson disease. Neurology. 2019;92(2):e148–e160. doi: 10.1212/WNL.0000000000006737
   PubMed Web of Science ®Google Scholar
• Chang Y, Wang L-B, Li D, et al. Efficacy of rasagiline for the treatment of Parkinson’s disease: an updated meta-analysis. Ann Med. 2017;49(5):421–434. doi: 10.1080/07853890.2017.1293285
   PubMed Web of Science ®Google Scholar
• Kano O, Tsuda H, Hayashi A, et al. Rasagiline as adjunct to levodopa for treatment of Parkinson’s disease: a systematic review and meta-analysis. Parkinsons Dis. 2022;2022:4216452. doi: 10.1155/2022/4216452
   PubMedGoogle Scholar
• Fahn S, Elton R. Members of the UPDRS development committee. The Unified Parkinson’s disease Rating scale. In: Fahn S, Marsden C Calne D, et al. Eds. Recent developments in Parkinson’s disease. Vol. 2. Florham Park (NJ): Macmillan Health Care Information; 1987. p. 153–163, 293–304.
   Google Scholar
• Goetz CG, Fahn S, Martinez-Martin P, et al. Movement disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41–47. doi: 10.1002/mds.21198
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170. doi: 10.1002/mds.22340
   PubMed Web of Science ®Google Scholar